Clinical trial
Paclitaxel, Topotecan, and Cisplatin in Treating Patients With Advanced…
NCT00276796 · Gynecologic Oncology Group, Other · Completed
Key facts
| NCT number | NCT00276796 |
|---|---|
| Title | Paclitaxel, Topotecan, and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer |
| Official title | A Limited Access Phase II Trial of Weekly Topotecan (NSC #609699), Paclitaxel (NSC #673089), and Cisplatin (NSC #119875) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix |
| Lead sponsor | Gynecologic Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cervical Cancer |
| Intervention type | Drug |
| Interventions | cisplatin, paclitaxel, topotecan hydrochloride |
| Enrollment | 66 |
| Primary completion | Jan 1, 2007 |
| First posted | Jan 13, 2006 |
| Last update posted | May 27, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: